Vonoprazan

Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H+, K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori[1][2][3].

Product Specifications

CAS Number

[881681-00-1]

Product Name Alternative

TAK-438 (free base)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bacterial; Proton Pump

Type

Reference compound

Related Pathways

Anti-infection; Membrane Transporter/Ion Channel

Field of Research

Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/TAK-438-free-base.html

Purity

99.89

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S(N1C=C(CNC)C=C1C2=CC=CC=C2F)(C3=CC=CN=C3)=O

Molecular Formula

C17H16FN3O2S

Molecular Weight

345.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Arikawa Y, et al. Discovery of a novel pyrrole derivative 1-[5- (2-fluorophenyl) -1- (pyridin-3-ylsulfonyl) -1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB) . J Med Chem, 2012, 55 (9), 4446-4456.|[2]Hori Y, et al. 1-[5- (2-Fluorophenyl) -1- (pyridin-3-ylsulfonyl) -1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 2010, 335 (1), 231-238.|[3]Sugimoto M, et al. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 2019 Jan 15;9:1560.